Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17490368 | 1.00 | SLC6A4 (0.31) | SLC6A4SLC6A3 | |
| SCHEMBL17490364 | 1.00 | SLC6A4 (0.31) | SLC6A4SLC6A3 | |
| SCHEMBL131715 | 0.83 | — | — | |
| SCHEMBL5868545 | 0.80 | SLC6A4 (0.35) | SLC6A4SLC6A3 | |
| SCHEMBL12344782 | 0.74 | — | — | |
| SCHEMBL1470750 | 0.73 | SLC6A4 (0.31) | SLC6A4SLC6A3 | |
| SCHEMBL4337964 | 0.72 | SLC6A4 (0.33) | SLC6A4SLC6A3 | |
| SCHEMBL25910376 | 0.72 | SLC6A4 (0.33) | SLC6A4SLC6A3 | |
| SCHEMBL10089210 | 0.72 | SLC6A4 (0.33) | SLC6A4SLC6A3 | |
| SCHEMBL17487272 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3174877-B1 | INDOLIZINE DERIVATIVES WHICH ARE APPLICABLE TO NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2022-06-29 | — | — | EP | disclosed |
| US-20170079965-A1 | NOVEL INDOLIZINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
| US-9546166-B2 | Indolizine derivatives and their use in neurodegenerative diseases | MERCK PATENT GMBH (DE) | 2017-01-17 | — | — | US | disclosed |
| US-20160031879-A1 | NOVEL INDOLIZINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2016-02-04 | — | — | US | disclosed |
| WO-2016019228-A1 | INDOLIZINE DERIVATIVES WHICH ARE APPLICABLE TO NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2016-02-04 | — | — | WO | disclosed |
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-8093265-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093265-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20080287415-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | SECOND GENOME, INC. | 2008-11-20 | — | — | US | disclosed |
| US-20080287415-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | SECOND GENOME, INC. | 2008-11-20 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
| WO-2008112205-A1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287415-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | SLC6A4 2165/4885SLC6A3 2573/4885 |
| US-20170079965-A1 | NOVEL INDOLIZINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | P2RX5, P2RX4, P2RX3 | SLC6A4 108/4885SLC6A3 171/4885 |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | SLC6A4 1359/4885SLC6A3 1466/4885 |
| US-20160031879-A1 | NOVEL INDOLIZINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | P2RX5, P2RX4, P2RX3 | SLC6A4 108/4885SLC6A3 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.